Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Has this medtech company created a new vital sign?

  • In News
  • September 27, 2021
  • Samantha Freidin
Has this medtech company created a new vital sign?

Vital signs are important indicators of health, however, they often don’t show the whole picture. Technological advancements in the medtech world are equipping clinicians with valuable, detailed insights into their patients’ health, assisting with clinical decision making and optimising patient outcomes. 

With over 700 devices in clinical use worldwide, Impedimed’s (ASX: IPD) clinically validated, fully approved tech is quickly becoming the new vital sign, giving doctors key information to support treatment. The SOZO Digital Health Platform works using bioimpedance technology, a low cost, non-invasive way to determine critical information about the human body, namely body composition. 

Designed to be minimally invasive and easy to use, the SOZO device requires patients to stand on a platform with bare feet and place their hands on touch pads. The device sends an electric current through the body that is not felt by the patient and measures using bioimpedenace spectroscopy. Results are available within 30 seconds and are available to view immediately on the device or online. 

The ability to determine the fluid balance within the body has important implications in treating heart failure, which affects approximately 26 million people per year globally. Current technologies to determine fluid burden include traditional weight scales or implantable pulmonary artery pressure monitors. The SOZO system provides an objective measure of fluid volume, removing the guesswork and inaccuracies of scales as well as the invasive procedures required for artery pressure monitors. The Company is keenly interested in forging partnerships in this area of cardiology. 

The device has caught the attention of Dr. Alii Valika, MD, an interventional cardiology specialist who is board certified in Advanced Heart Failure and Transplant Cardiology. Dr. Valika has been central in establishing the SOZO Heart Failure Program at Advocate Health Care’s Heart Institute located in Chicago, Illinois. 

The Heart Institute is within the Advocate Health Group with over 100 sites where 350 specialists undertake more than 20,000 procedures per year. 

The introduction of the SOZO Heart Failure Program is primarily aimed at maintaining and monitoring optimal fluid levels in heart failure patients, both in the clinic and post discharge. 

The Group already has 10 SOZO devices under their Lymphoedema Prevention Program, the new Heart Failure Program will see the amount of devices in the network increase. 

Richard Carreon, Managing Director and CEO of Impedimed welcomed the partnership, saying: “After the significant COVID-19 delays it is fantastic to initiate the SOZO heart failure program at such a highly respected and credentialed medical institution. We are looking forward to working with Dr. Valika and his team in advancing the use of SOZO and improving outcomes in the heart failure patients. We are expecting other hospitals to initiate SOZO heart failure programs shortly, adding to the clinical and reimbursement evidence required to underpin widespread commercialisation.” 

The move towards highly accurate body composition measurements has applications reaching far beyond cardiology including in dialysis patients, in oncology and rehab and therapy. 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.